These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30848434)

  • 1. Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.
    McCafferty EH; Scott LJ
    BioDrugs; 2019 Apr; 33(2):233-240. PubMed ID: 30848434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
    Wang RY; da Silva Franco JF; López-Valdez J; Martins E; Sutton VR; Whitley CB; Zhang L; Cimms T; Marsden D; Jurecka A; Harmatz P
    Mol Genet Metab; 2020 Mar; 129(3):219-227. PubMed ID: 32063397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease.
    Harmatz P; Whitley CB; Wang RY; Bauer M; Song W; Haller C; Kakkis E
    Mol Genet Metab; 2018 Apr; 123(4):488-494. PubMed ID: 29478819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
    Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
    Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program.
    Giugliani R; Gonzalez-Meneses A; Scarpa M; Burton B; Wang R; Martins E; Oussoren E; Hennermann JB; Chabrol B; Grant CL; Sun A; Durand C; Hetzer J; Malkus B; Marsden D; Merritt Ii JL
    Orphanet J Rare Dis; 2024 May; 19(1):189. PubMed ID: 38715031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
    Lau HA; Viskochil D; Tanpaiboon P; Lopez AG; Martins E; Taylor J; Malkus B; Zhang L; Jurecka A; Marsden D
    Mol Genet Metab; 2022 May; 136(1):28-37. PubMed ID: 35331634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
    Qi Y; McKeever K; Taylor J; Haller C; Song W; Jones SA; Shi J
    Clin Pharmacokinet; 2019 May; 58(5):673-683. PubMed ID: 30467742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
    Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII.
    Jones S; Coker M; López AG; Sniadecki J; Mayhew J; Hensman P; Jurecka A
    Mol Genet Metab Rep; 2021 Sep; 28():100774. PubMed ID: 34136357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population.
    Haller C; Song W; Cimms T; Chen CY; Whitley CB; Wang RY; Bauer M; Harmatz P
    JIMD Rep; 2019 Sep; 49(1):53-62. PubMed ID: 31497482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.
    Vogler C; Levy B; Galvin NJ; Thorpe C; Sands MS; Barker JE; Baty J; Birkenmeier EH; Sly WS
    Pediatr Res; 1999 Jun; 45(6):838-44. PubMed ID: 10367775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse.
    Vogler C; Sands M; Higgins A; Levy B; Grubb J; Birkenmeier EH; Sly WS
    Pediatr Res; 1993 Dec; 34(6):837-40. PubMed ID: 8108204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
    Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
    Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs.
    Gawri R; Lau YK; Lin G; Shetye SS; Zhang C; Jiang Z; Abdoun K; Scanzello CR; Jo SY; Mai W; Dodge GR; Casal ML; Smith LJ
    Mol Ther Methods Clin Dev; 2023 Mar; 28():12-26. PubMed ID: 36570425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.
    Vogler C; Levy B; Grubb JH; Galvin N; Tan Y; Kakkis E; Pavloff N; Sly WS
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14777-82. PubMed ID: 16162667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Report of a Patient with MPS Type VII, Due to Novel Mutations in
    Dubot P; Sabourdy F; Plat G; Jubert C; Cancès C; Broué P; Touati G; Levade T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote.
    Vervoort R; Gitzelmann R; Bosshard N; Maire I; Liebaers I; Lissens W
    Hum Genet; 1998 Jan; 102(1):69-78. PubMed ID: 9490302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.
    Rowan DJ; Tomatsu S; Grubb JH; Haupt B; Montaño AM; Oikawa H; Sosa AC; Chen A; Sly WS
    Mol Genet Metab; 2012 Sep; 107(1-2):161-72. PubMed ID: 22902520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII.
    Woloszynek JC; Roberts M; Coleman T; Vogler C; Sly W; Semenkovich CF; Sands MS
    Biochem J; 2004 Apr; 379(Pt 2):461-9. PubMed ID: 14705966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy for murine mucopolysaccharidosis type VII.
    Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH
    J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.